[go: up one dir, main page]

CL2012000886A1 - Polipeptido que comprende dos secuencias aminoacidas que permiten la union especifica al receptor para productos finales de glicosilacion avanzada (rpfga); uno o mas acidos nucleicos que codifican el polipeptido; celula; composicion; metodo para diagnosticar enfermedad o trastorno con rpfga. - Google Patents

Polipeptido que comprende dos secuencias aminoacidas que permiten la union especifica al receptor para productos finales de glicosilacion avanzada (rpfga); uno o mas acidos nucleicos que codifican el polipeptido; celula; composicion; metodo para diagnosticar enfermedad o trastorno con rpfga.

Info

Publication number
CL2012000886A1
CL2012000886A1 CL2012000886A CL2012000886A CL2012000886A1 CL 2012000886 A1 CL2012000886 A1 CL 2012000886A1 CL 2012000886 A CL2012000886 A CL 2012000886A CL 2012000886 A CL2012000886 A CL 2012000886A CL 2012000886 A1 CL2012000886 A1 CL 2012000886A1
Authority
CL
Chile
Prior art keywords
rpfga
polypeptide
disorder
receptor
amino acid
Prior art date
Application number
CL2012000886A
Other languages
English (en)
Inventor
Jochen Huber
Francis Blanche
Tarik Dabdoubi
Fabienne Soubrier
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP09290778A external-priority patent/EP2308896A1/en
Priority claimed from EP09290845A external-priority patent/EP2319871A1/en
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of CL2012000886A1 publication Critical patent/CL2012000886A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)

Abstract

Polipéptido que comprende dos secuencias aminoácidas que permiten la unión específica al receptor para productos finales de glicosilación avanzada (RPFGA); uno o más ácidos nucleicos que codifican el polipéptido; célula; composición; método para diagnosticar enfermedad o trastorno con RPFGA.
CL2012000886A 2009-10-09 2012-04-05 Polipeptido que comprende dos secuencias aminoacidas que permiten la union especifica al receptor para productos finales de glicosilacion avanzada (rpfga); uno o mas acidos nucleicos que codifican el polipeptido; celula; composicion; metodo para diagnosticar enfermedad o trastorno con rpfga. CL2012000886A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09290778A EP2308896A1 (en) 2009-10-09 2009-10-09 Polypeptides for binding to the "receptor for advanced glycation endproducts" as well as compositions and methods involving the same
EP09290845A EP2319871A1 (en) 2009-11-05 2009-11-05 Polypeptides for binding to the "receptor for advanced glycation endproducts" as well as compositions and methods involving the same

Publications (1)

Publication Number Publication Date
CL2012000886A1 true CL2012000886A1 (es) 2012-12-14

Family

ID=43448431

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012000886A CL2012000886A1 (es) 2009-10-09 2012-04-05 Polipeptido que comprende dos secuencias aminoacidas que permiten la union especifica al receptor para productos finales de glicosilacion avanzada (rpfga); uno o mas acidos nucleicos que codifican el polipeptido; celula; composicion; metodo para diagnosticar enfermedad o trastorno con rpfga.

Country Status (20)

Country Link
US (1) US20120282637A1 (es)
EP (1) EP2486058A1 (es)
JP (1) JP2013507115A (es)
KR (1) KR20120089863A (es)
CN (1) CN102686611A (es)
AU (1) AU2010305374A1 (es)
BR (1) BR112012007821A2 (es)
CA (1) CA2777237A1 (es)
CL (1) CL2012000886A1 (es)
CR (1) CR20120139A (es)
EC (1) ECSP12011787A (es)
IL (1) IL218968A0 (es)
MA (1) MA33661B1 (es)
MX (1) MX2012004090A (es)
PE (1) PE20121689A1 (es)
PH (1) PH12012500564A1 (es)
RU (1) RU2558301C2 (es)
TN (1) TN2012000138A1 (es)
WO (1) WO2011042548A1 (es)
ZA (1) ZA201202099B (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA112434C2 (uk) 2011-05-27 2016-09-12 Ґлаксо Ґруп Лімітед Антигензв'язувальний білок, який специфічно зв'язується з всма
GB201200563D0 (en) * 2012-01-13 2012-02-29 Imp Innovations Ltd Binding molecule
WO2014167826A1 (ja) * 2013-04-08 2014-10-16 株式会社免疫生物研究所 アミロイド前駆体タンパク質のα－セクレターゼ切断後のＣ末端側断片の切断面を特異的に認識する抗体及びその利用
WO2014197460A1 (en) * 2013-06-04 2014-12-11 The Trustees Of The University Of Pennsylvania Methods for diagnosing and treating bicuspid aortic valve and/or aortopathies
HRP20211317T1 (hr) 2013-08-30 2021-11-26 Immunogen, Inc. Antitijela i analize za detekciju folat receptora 1
EP3077823B1 (en) 2013-12-05 2019-09-04 The Broad Institute, Inc. Compositions and methods for identifying and treating cachexia or pre-cachexia
US20170240632A1 (en) * 2014-10-16 2017-08-24 The Broad Institute Inc. Compositions and methods for identifying and treating cachexia or pre-cachexia
JP6679096B2 (ja) * 2014-10-21 2020-04-15 学校法人 久留米大学 Ｒａｇｅアプタマーおよびその用途
WO2016070001A1 (en) * 2014-10-31 2016-05-06 Jounce Therapeutics, Inc. Methods of treating conditions with antibodies that bind b7-h4
WO2016183352A1 (en) * 2015-05-12 2016-11-17 Syntimmune, Inc. Humanized affinity matured anti-fcrn antibodies
US10787517B2 (en) 2015-05-18 2020-09-29 Agensys, Inc. Antibodies that bind to AXL proteins
WO2016187354A1 (en) 2015-05-18 2016-11-24 Agensys, Inc. Antibodies that bind to axl proteins
WO2016201319A1 (en) * 2015-06-10 2016-12-15 The Broad Institute Inc. Antibodies, compounds and screens for identifying and treating cachexia or pre-cachexia
EP3822291A1 (en) 2015-06-10 2021-05-19 The Broad Institute Inc. Antibodies, compounds and screens for identifying and treating cachexia or pre-cachexia
JP6578595B2 (ja) * 2015-08-28 2019-09-25 国立研究開発法人科学技術振興機構 抗アセチル化ヒストンｈ４抗体
MX377865B (es) * 2015-09-08 2025-03-10 Eisai R&D Man Co Ltd Anticuerpo anti-epha4.
IL257531B2 (en) 2015-09-17 2023-04-01 Immunogen Inc Medicinal compositions containing anti-folr1 immunoconjugates
US11111296B2 (en) 2015-12-14 2021-09-07 The Broad Institute, Inc. Compositions and methods for treating cardiac dysfunction
CN113512111B (zh) * 2017-03-10 2023-08-15 北京天广实生物技术股份有限公司 抗埃博拉病毒单克隆抗体、其制备方法及用途
SG11202000053TA (en) 2017-08-02 2020-02-27 Phanes Therapeutics Inc Anti-cd47 antibodies and uses thereof
JP2021521110A (ja) 2018-04-06 2021-08-26 エータイアー ファーマ， インコーポレイテッド 抗ｎｒｐ２抗体を含む組成物及び方法
US11345744B2 (en) 2019-05-07 2022-05-31 William R Church Antibody specific to Staphylococcus aureus, therapeutic method and detection method using same
BR112021025476A2 (pt) * 2019-06-26 2022-10-11 Glaxosmithkline Ip Dev Ltd Proteínas de ligação à il1rap
EP4037711A4 (en) * 2019-10-03 2024-02-14 Atyr Pharma, Inc. COMPOSITIONS AND METHODS USING ANTI-NRP2 ANTIBODIES
WO2022019924A1 (en) * 2020-07-23 2022-01-27 Church William R Antibody specific to staphylococcus aureus, therapeutic method and detection method using same
CN113956363B (zh) * 2021-10-13 2023-03-31 宜明昂科生物医药技术（上海）股份有限公司 靶向cd47和cd24的重组融合蛋白及其制备和用途
US20250011424A1 (en) * 2021-11-18 2025-01-09 Salvarx Llc Antibodies to receptor of advanced glycation end products (rage) and uses thereof
CN116554311B (zh) * 2023-05-04 2023-11-21 中国人民解放军军事科学院军事医学研究院 抗CD2v-N的特异性抗体及其应用
KR20250001879A (ko) 2023-06-28 2025-01-07 주식회사 세바바이오텍 완도호랑가시나무와 노루궁뎅이버섯 추출물을 유효성분으로 포함하는 최종당화산물 억제용 조성물

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
DK0772619T4 (da) 1994-07-15 2011-02-21 Univ Iowa Res Found Immunmodulatoriske oligonukleotider
US5864018A (en) * 1996-04-16 1999-01-26 Schering Aktiengesellschaft Antibodies to advanced glycosylation end-product receptor polypeptides and uses therefor
MY131805A (en) * 1997-09-18 2007-09-28 Biogen Idec Inc Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesis.
AT409085B (de) 2000-01-28 2002-05-27 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen
AT410173B (de) 2000-06-08 2003-02-25 Cistem Biotechnologies Gmbh Antigene zusammensetzung
CA2411575C (en) 2000-06-08 2015-04-07 Walter Schmidt Immunostimulatory oligodeoxynucleotides
CA2418854A1 (en) 2000-08-17 2002-02-21 Jorg Fritz A vaccine which comprises at least one antigen and a cathelididin derived antimicrobial peptide or a derivative thereof
AT410635B (de) 2000-10-18 2003-06-25 Cistem Biotechnologies Gmbh Vakzin-zusammensetzung
CA2448031A1 (en) 2001-05-21 2002-11-28 Intercell Ag Method for stabilising of nucleic acids
US7425328B2 (en) * 2003-04-22 2008-09-16 Purdue Pharma L.P. Tissue factor antibodies and uses thereof
US20080008719A1 (en) * 2004-07-10 2008-01-10 Bowdish Katherine S Methods and compositions for the treatment of prostate cancer
RU2008139098A (ru) * 2006-03-02 2010-04-10 Онкотерапи Сайенс, Инк. (Jp) Способы диагностики рака поджелудочной железы с применением белка reg4
CN101448857A (zh) * 2006-03-21 2009-06-03 惠氏公司 预防和治疗淀粉样蛋白生成疾病的方法
WO2007109749A2 (en) * 2006-03-21 2007-09-27 Wyeth Methods for preventing and treating amyloidogenic diseases
WO2007147901A1 (en) * 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
CN100586960C (zh) * 2006-06-23 2010-02-03 陈志南 HAb18GC2单抗和其轻、重链可变区基因及应用
WO2008137552A2 (en) * 2007-05-02 2008-11-13 Medimmune, Llc Anti-rage antibodies and methods of use thereof
SG188142A1 (en) * 2008-05-09 2013-03-28 Abbott Gmbh & Co Kg Antibodies to receptor of advanced glycation end products (rage) and uses thereof

Also Published As

Publication number Publication date
PH12012500564A1 (en) 2012-10-22
EP2486058A1 (en) 2012-08-15
ECSP12011787A (es) 2012-10-30
CN102686611A (zh) 2012-09-19
TN2012000138A1 (en) 2013-09-19
RU2558301C2 (ru) 2015-07-27
CR20120139A (es) 2012-07-13
US20120282637A1 (en) 2012-11-08
MA33661B1 (fr) 2012-10-01
CA2777237A1 (en) 2011-04-14
WO2011042548A1 (en) 2011-04-14
MX2012004090A (es) 2012-04-20
AU2010305374A1 (en) 2012-05-03
RU2012118598A (ru) 2013-11-20
BR112012007821A2 (pt) 2017-05-30
PE20121689A1 (es) 2012-12-14
JP2013507115A (ja) 2013-03-04
IL218968A0 (en) 2012-07-31
ZA201202099B (en) 2012-11-28
KR20120089863A (ko) 2012-08-14

Similar Documents

Publication Publication Date Title
CL2012000886A1 (es) Polipeptido que comprende dos secuencias aminoacidas que permiten la union especifica al receptor para productos finales de glicosilacion avanzada (rpfga); uno o mas acidos nucleicos que codifican el polipeptido; celula; composicion; metodo para diagnosticar enfermedad o trastorno con rpfga.
CL2013000475A1 (es) Polipeptidos de relaxina que comprende uno o mas aminoacidos codificados no naturales; acido nucleico aislado; metodo para preparar el polipeptido de relaxina.
EA201590994A1 (ru) Способ увеличения гидродинамического объема полипептида путем присоединения карбоксиконцевого пептида гонадотропина
BR112012011305A2 (pt) uso de uma proteína homóloga a uma proteína meab para aumentar a atividade enzimática de uma mutase do ácido 3-hidroxicarboxílico-coa
ECSP12011577A (es) Produccion recombinante de péptidos
CL2014000699A1 (es) Proteina de union al antigeno cd27l; acido nucleico que la codifica; vector de expresion; celula huesped recombinante; composicion que la comprende; su uso para tratar cancer, trastornos autoinmunitarios o inflamatorios; y metodo para elaborar un conjugado anticuerpo cd27l-farmaco.
CL2012001539A1 (es) Anticuerpo 005-c04 que antagonizan la señalizacion mediada por el receptor de prolactina; secuencia de acido nucleico que codifica dicho anticuerpo; vector de expresion y célula huesped que comprenden dicha secuencia de acido nucleico; uso del anticuerpo para terapia hormonal combinada; composicion farmacéutica que comprende el anticuerpo.
PE20160718A1 (es) Polipeptidos mutantes fgf21
UY32501A (es) Anticuerpo antagonista específico para el heterodímero alfa4-beta7
CR20130667A (es) Composiciones que contienen, mètodos que involucran, y usos derivados de dolastatina unidos a aminoàcidos no naturales
BR112012015740A2 (pt) anticorpos de anti-flt3 e metodos de uso dos mesmos
CL2013001831A1 (es) Proteina de enlace multivalente y multiespecifica que une a il-1 alfa y beta; conjugado que la comprende; acido nucleico que la codifica; vector; celula huesped; metodo de produccion; composicion farmaceutica que la comprende; y sus usos.
BR112017023646A2 (pt) proteínas agonistas de receptor de cd40 de cadeia simples
BR112012004697A2 (pt) purificação melhorada de proteína através de uma eluição da proteína a modificada.
UY33578A (es) PÉPTIDO O COMPLEJO PEPTÍDICO QUE SE UNE A INTEGRINA a(ALFA) Y MÉTODOS Y USOS QUE IMPLICAN A LOS MISMOS
CO6290770A2 (es) Nuevos derivados de insulina con perfil tiempo/accion extremadamente retardado
JOP20200039A1 (ar) مُستحضر صيدلي يشتمل على hcg مأشوب
BR112013000623A2 (pt) purificação de proteína.
BRPI0906795A2 (pt) Método para produzir um l-aminoácido
BRPI0918299A2 (pt) Método para produzir um l-aminoácido
BR112013012786A2 (pt) módulos melhorados de tamponamento do terminal de n para as proteínas com repetições de anquirina planejada
MX358249B (es) Proteínas de enlace al antígeno il-23 humanas.
BR112018077188A2 (pt) frutose-6-fosfato-3-epimerase termoestável inovadora e um método para produzir alulose com o uso da mesma
UA110599C2 (uk) Пептид для імунотерапії пухлин, включаючи нейрональні пухлини та пухлини мозку
AR067666A1 (es) Proteinas de union al antigeno del receptor de il-18